STOCKS TO WATCH: No booster for boss as GSK's Novavax deal is off
GSK had planned to start working on the manufacture of up to 60million doses of the jab from as early as May 2021.
GSK had planned to start working on the manufacture of up to 60million doses of the jab from as early as May 2021.